(1888PressRelease)
October 27, 2009 - Hyderabad - Granules India Ltd., a leading manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs), announced financial results for its fiscal year 2010 second quarter ended September 30, 2009. Granules posted revenue of Rs. 96.44 Cr. which is the highest revenue achieved in a quarter by the Company and a net profit of Rs. 6.07 Cr., reflecting an increase of 18.4% and 121.3% over the same period last year, respectively.
Quarter ended September 30th 2009
• Net Sales: Rs. 96.44 Cr, as compared to the same period over the previous year at Rs. 81.45 Cr. The increase is attributed to the Company’s focus on international markets.
• Profit Before Tax (PBT): Rs. 7.42 Cr, as compared to the same period over the previous year at Rs. 3.54 Cr, an increase of 109%.
• Net Profit: Rs. 6.07 Cr, as compared to the same period over the previous year of Rs. 2.74 Cr, an increase of 121%.
• EPS: Basic EPS was Rs. 3.02 as compared to the same period over the previous year at Rs. 1.37, an increase of 120%.
The Company achieved a turnover of Rs. 114.55 Cr. on a consolidated basis and a net profit of Rs. 7.75 Cr. The consolidated accounts include a joint-venture and subsidiaries.
“Increased production across our value chain contributed to our growth, including our PFI unit at Jeedimetla which had substantial increases in capacity utilization. However, it is our Finished Dosage sales which showed the most improvement. Net sales for our Finished Dosages are Rs. 10.20 Cr. for the quarter which is up by 69% compared to previous quarter. For the remaining fiscal year, we expect finished dosage production to increase even further and to continue to be a main driver for our growth.” said C. Krishna Prasad, Managing Director of Granules.
About Granules India Ltd.
(BSE: 532482, NSE: GRANULES)
Granules India Ltd. is a fully integrated pharmaceutical manufacturer. The Company manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs) which are distributed in over 50 countries. The Company has recently started manufacturing finished dosages with a plant that has a capacity of 6 billion tablets per annum, scalable to 12 billion tablets. This facility will allow Granules to offer products across the value chain.
###
